Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | CES1 | P23141 | 4/20 | 0.44 |
| ▸ | CES2 | O00748 | 3/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9311224 | 0.76 | TSHR (0.52) | TSHRCES1CES2SRCLMNA | |
| SCHEMBL15988227 | 0.74 | TSHR (0.56) | TSHRCES1CES2SRCLMNA | |
| SCHEMBL1193711 | 0.74 | TSHR (0.56) | TSHRCES1CES2SRCLMNA | |
| SCHEMBL10873087 | 0.74 | TSHR (0.56) | TSHRCES1CES2SRCLMNA | |
| SCHEMBL93631 | 0.74 | TSHR (0.56) | TSHRCES1CES2SRCLMNA | |
| SCHEMBL4019330 | 0.74 | TSHR (0.56) | TSHRCES1CES2SRCLMNA | |
| SCHEMBL1603720 | 0.74 | TSHR (0.56) | TSHRCES1CES2SRCLMNA | |
| SCHEMBL25137264 | 0.74 | TSHR (0.50) | TSHRCES1CES2SRCLMNA | |
| SCHEMBL17895051 | 0.74 | MAPT (0.47) | CES1CES2LMNAMAPK1L3MBTL1 | |
| SCHEMBL5080161 | 0.74 | TSHR (0.50) | TSHRCES1CES2SRCLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3089980-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2018-01-31 | — | — | EP | claimed |
| US-9670208-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-06-06 | — | — | US | claimed |
| EP-3089980-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2016-11-09 | — | — | EP | claimed |
| US-20160304519-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-10-20 | — | — | US | claimed |
| WO-2015103137-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2015-07-09 | — | — | WO | claimed |
| CN-101189246-B | Process for the production of isocyanatosilane and silylisocyanurate | MOMENTIVE PERFORMANCE MAT INC | 2012-08-08 | — | — | CN | claimed |
| CN-101759883-A | Rubber composition | KOREA TYRE CO LTD | 2010-06-30 | — | — | CN | claimed |
| CN-101268087-A | Method for production of isocyanatosilanes | MOMENTIVE PERFORMANCE MAT INC (US) | 2008-09-17 | — | — | CN | claimed |
| CN-101189246-A | Process for the production of isocyanatosilane and silylisocyanurate | MOMENTIVE PERFORMANCE MAT INC (US) | 2008-05-28 | — | — | CN | claimed |
| US-7247687-B2 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-07-24 | — | — | US | claimed |
| CN-1965377-A | Anti-corrosion additive for electrical cable restoration fluids | DOW CORNING (US) | 2007-05-16 | — | — | CN | claimed |
| EP-1521758-B1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEM PATENTS INC (US) | 2006-05-24 | — | — | EP | claimed |
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2006-03-02 | — | — | US | claimed |
| US-4479966-A | 6,9-Methano-PGI2 analogues | ONO PHARMACEUTICAL COMPANY, LTD. (JP) | 1984-10-30 | — | — | US | claimed |
| EP-0073566-A1 | Methods and compositions for combating soil pests | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-03-09 | — | — | EP | claimed |
| US-11376260-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210106593-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-4390548-A | Trans-Δ2 -pge alkylsulphonyl amides | ONO PHARMACEUTICAL CO., LTD. (JP) | 1983-06-28 | — | — | US | disclosed |
| US-4367237-A | THIOPGI-1 DERIVATIVES; OXYTOCICS; PREFERENTIAL | ONO PHARMACEUTICAL CO., LTD. (JP) | 1983-01-04 | — | — | US | disclosed |
| US-4351846-A | 3-Hydroxy and 3-oxo-prostaglandin analogues | ONO PHARMACEUTICAL CO., LTD. (JP) | 1982-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376260-B2 | Serine/threonine kinase inhibitors | MAP3K1, MAP3K4, MAP4K2 | TSHR 2044/4885CES1 2991/4885CES2 4564/4885 |
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | MLX, LOX, LMTK3 | TSHR 4680/4885CES1 4486/4885CES2 4281/4885 |
| US-20160304519-A1 | SERINE/THREONINE KINASE INHIBITORS | TTBK1, MAP3K1, TNNI3K | TSHR 2352/4885CES1 2173/4885CES2 4081/4885 |
| US-20210106593-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K4, MAP4K2 | TSHR 2044/4885CES1 2991/4885CES2 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.